Drug intelligence / Profile preview

GS-220

Development stage: Preclinical
Lead developer: Grace Science
Modality: Small Molecules

Overview

GS-220 is a preclinical **small molecule** oncology candidate from **Grace Science** being developed for **undisclosed cancers**. It is described as an **NGLY1 inhibitor** that indirectly suppresses **NFE2L1** signaling by blocking NGLY1 activity, thereby shutting down a downstream transcription-factor pathway that is considered difficult to inhibit directly. The program is part of Grace Science's oncology pipeline alongside GS-221 and reflects the company's strategy of leveraging NGLY1 biology beyond its rare disease programs.

Targets

NFE2L1 (Nuclear respiratory factor 1)NGLY1 (N-glycanase 1)

Beyond the preview

Go deeper on GS-220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-220.

Explore the full profile